ArticleFrontiers in urology2025
Impact of the coronavirus disease 2019 (COVID-19) pandemic on tumor stage progression in urological malignancies: a comparative study.
Article in Frontiers in urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical Oncologists for Sustainability: A Statement from the SSO Surgical Oncologists for Sustainability Committee.Annals of surgical oncology · 2026Review
- Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.Pathology oncology research : POR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether delays in care during the coronavirus pandemic 2019 (COVID-19) were associated with pathological stage progression in urological malignancies by comparing surgical outcomes between pre-pandemic era (PREP) and pandemic-era (POSTP) cohorts. Methods: We conducted a retrospective before-and-after cohort study at a tertiary academic center. A total of 368 patients underwent radical surgeries for prostate (n=176), bladder (n=78), kidney (n=78), or testicular (n=36) cancers between April 2019 and March 2022. Patients were grouped into PREP (April 2019-March 2020) and POSTP (April 2020-March 2022) cohorts. Clinical, laboratory, and pathological data were compared using Student's t-test, Mann-Whitney U test, Chi-square test, or Fisher's exact test, with p<0.05 considered statistically significant. Results: POSTP prostatectomy patients had significantly higher preoperative PSA levels (13.2 ± 16.2 vs. 7.7 ± 4.5 ng/mL, p<0.001), greater tumor involvement (17.0% vs. 11.5%, p=0.019), and increased extraprostatic extension (33.7% vs. 11.9%, p=0.006) compared to PREP patients. Renal tumors were significantly larger during the pandemic (7.4 cm vs. 6.0 cm, p=0.01), and preoperative hemoglobin levels were lower (11.7 vs. 12.9 g/dL, p<0.001), suggesting more advanced disease. No statistically significant differences were observed in pathological staging for bladder or testicular cancers between the two periods (all p>0.05). Conclusion: COVID-19-related care disruptions were associated with adverse pathological features in prostate and renal cancers. In contrast, bladder and testicular cancers showed no significant stage migration. These findings emphasize the need for resilient cancer care pathways to prevent progression during future healthcare crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.